28290-41-7

Basic information

• Product Name: TRANS,TRANS-FARNESYL BROMIDE
• Synonyms: FARNESYL BROMIDE;TRANS,TRANS-1-BROMO-3,7,11-TRIMETHYL-2,6,10-DODECATRIENE;TRANS,TRANS-FARNESYL BROMIDE;1-Bromo-3,7,11-trimethyl-2,6,10-dodecatriene;3,7,11-Trimethyl-2,6,10-dodecatrienyl bromide;(E,E)-Farnesyl Bromide;(2E,6E)-;trans,trans-Farnesyl bromide 95%
• CAS NO: 28290-41-7
• Molecular Formula: C₁₅H₂₅Br
• Molecular Weight: 285.26
• Product Categories: Mixed Fatty Acids;Fatty Acid Derivatives & Lipids;Glycerols;Aliphatics
• Mol File: 28290-41-7.mol
• Article Data: 87

Chemical Properties

• Boiling Point: 100-110 °C15 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.052 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.000267mmHg at 25°C
• Refractive Index: n20/D 1.509(lit.)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: TRANS,TRANS-FARNESYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: TRANS,TRANS-FARNESYL BROMIDE(28290-41-7)
• EPA Substance Registry System: TRANS,TRANS-FARNESYL BROMIDE(28290-41-7)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41
• Safety Statements: 26-39
• RIDADR: UN 3334
• WGK Germany: 3
• Hazardous Substances Data: 28290-41-7(Hazardous Substances Data)

Usage

Chemical Properties

Brown Oil

Uses

Different sources of media describe the Uses of 28290-41-7 differently. You can refer to the following data:
1. An analog of Farnesol, produced in the dimorphic fungus Candida albicans
2. Farnesyl bromide was used in the preparation of:S-trans, trans-farnesyl-L-cysteine methylester, a post translational modified amino acidumbelliprenin, starting reagent for the synthesis of (±)-farnesiferol A and (±)-farnesiferol Cprenylated peptides

InChI:InChI=1/C15H25Br/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11H,5-6,8,10,12H2,1-4H3/b14-9+,15-11+

Upstream product

• 4602-84-0 farnesol 
• 106-28-5 Farnesol 
• 40716-66-3 (E)-3,7,11-trimethyl-1,6,10-dodecatrien-3-ol 
• 106-24-1 Geraniol 
• 6138-90-5 trans-geranyl bromide 
• 19894-78-1 (E)-2-acetyl-5,9-dimethyldeca-4,8-dienoic acid ethyl ester 
• 3796-70-1 trans geranyl acetone 
• 1119-38-6 (S)-(+)-nerolidol 
• 7212-44-4 (+/-)-nerolidol 
• 502-67-0 Farnesal 
• 56194-28-6 3,7,11-trimethyl-2ξ,6E,10-dodecatrien-1-ol 
• 19945-61-0 (E)-4,8-dimethylnona-1,3,7-triene 
• 4128-17-0 (2E,6E)-farnesyl acetate 
• 689-67-8 pseudo-ionone 

Downstream Products

• 19317-11-4 farnesal 
• 66958-75-6 1,4-Bis-benzyloxy-2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-28-(toluene-4-sulfonyl)-tetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-methyl-benzene 
• 56881-53-9 (E,E)-farnesyl phenylsulfone 
• 56881-54-0 2Z,6E-Farnesyl-phenyl-sulfon 
• 502-67-0 Farnesal 
• 94286-83-6 6-farnesyl-1,5-dimethoxy-3-methyl-1,4-cyclohexadiene 
• 84018-98-4 3-Hydroxy-4-methoxy-2-((2E,6E)-3,7,11-trimethyl-dodeca-2,6,10-trienyloxy)-benzaldehyde 
• 84018-86-0 2-Hydroxy-4-methoxy-3-((2E,6E)-3,7,11-trimethyl-dodeca-2,6,10-trienyloxy)-benzaldehyde 
• 84018-99-5 4-Methoxy-2,3-bis-((2E,6E)-3,7,11-trimethyl-dodeca-2,6,10-trienyloxy)-benzaldehyde 
• 64432-03-7 1,3-dimethoxy-5-methyl-2-<(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl>benzene 
• 111-02-4 2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene 
• 127044-34-2 4-Phenylsulfonyl-3,7,11,15-tetramethylhexadeca-2Z,6E,10E,14-tetraen-1-ol 
• 95778-33-9 1,2,3,4-tetramethoxy-5-methyl-6-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)benzene 
• 2102-72-9 asperugin 

Relevant articles and documents

CHINONE-, HYDROCHINOME- AND NAPHTHOCHINONE-ANALOGUES OF VATIQUIONE FOR TREATMENT OF MITOCHONDRIAL DISORDER DISEASES

The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g. Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).

ANTIBIOTIC COMPOUNDS

Provided herein are lipidated glycopeptide compounds of formula (I); or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof. R1 is a lipid, R2 is -H or a lipid, and R3 and R4 are as defined herein. These compounds have antibiotic activity. Also provided are formulations comprising such compounds; as well as such compounds or formulations for use as a medicament. The compounds and formulations may also be used in the treatment of bacterial infection.

Protein degradation targeting chimeric compound, preparation method and medical application thereof

The invention relates to a protein degradation targeting chimeric compound, a preparation method and medical application thereof, specifically to a compound as shown in a general formula (I), a preparation method of the compound, and application of the co